Epidemiology of rheumatoid arthritis

Slides:



Advertisements
Similar presentations
RHEUMATOID ARTHRITIS MUHAMMAD ADEEL (BIOT 412) Human Diseases Presentation.
Advertisements

Disease Modifying Anti-Rheumatic Drugs (DMARDs) Immunomodulatory and immunosuppresive Xenobiotic – Gold salts – Azathioprine – Methotrexate Biological.
NSAIDs 1 st line of therapy in the medical management of RA.
Efficacy of Methotrexate and/or Etanercept for treatment of RA Rheumatoid Arthritis:
Anti-Inflammatory & Immunosuppressive Drugs 2
Understanding the Immune System
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 69 Immunosuppressants.
תרופות בשימוש בראומטולוגיה פרופ. משה טישלר מחלקה פנימית ב והשרות הראומטולוגי בי " ח אסף הרופא צריפין.
DR.IBTISAM JALI MEDICAL DEMONSTRATOR
Drugs used in joint diseases
Familial metabolic disease Characterized by : Acute arthritis Uric stones in the kidneys Hyperuricemia.
+ Rheumatoid Arthritis Jocelin Olmos & Matt Scroggy.
Inflammatory bowel disease/ Irritable bowel syndrome Dr. Syed Md. Basheeruddin Asdaq.
Hot Topics in Rheumatology Prof. MG Molloy. Overview Rheumatoid Arthritis Psoriatic Arthritis Vasculitides: SLE Osteoarthritis Osteoporosis.
New Pharmacologic Treatment Options for Managing Rheumatoid Arthritis Devra Dang, Pharm.D. Department of Pharmacy National Institutes of Health.
Department of Pathology
Anti-Inflammatory & Immunosuppressive Drugs 2
Disease –Modifying Antirheumatic Drugs ( DMARDs) Slow Acting Anti-inflammatory Drugs.
Rheumatoid Arthritis(RA)
Cause of disability. Changes in the joint inflammation, proliferation of the synovium, errosion of cartilage & bones.
R HEUMATOID A RTHRITIS BMJ 2011;342: RA is a systemic inflammatory autoimmune disease with localised and general manifestations. It is characterised.
Recomendations for the medicamentous treatment of chronic inflammatory rheumatic disease pain Dušan Logar Dpt.of Rheumatology, University Clinical Centre,
Abrar M. Radwan Saleh Dr. Adham Abo-Taha An-Najah National University College of Pharmacy Pharmacy Program: Pharm D.
Disease –Modifying Antirheumatic drugs
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis.
Slow Acting Anti-inflammatory Drugs. DEFINITION Drugs used to relief pain & inflammation.
( Slow Acting Anti-inflammatory Drugs ). OBJECTIVES At the end of the lecture the students should Define DMARDs Describe the classification of this group.
Drugs used in inflammatory bowel disease and biological and immune therapy of IBD Prof. Hanan Hagar Pharmacology Department College of Medicine.
Kara Kliethermes Jim Shinaberry December 6, 2012.
Inflammatory bowel disease/ Irritable bowel syndrome Dr. Syed Md. Basheeruddin Asdaq.
Slow Acting Anti-inflammatory Drugs ). BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSF.
LSU Clinical Pharmacology
Approach to the Treatment of RA Try to figure out ‘what type’ of Rheumatoid Arthritis the patient has This is not a uniform disease Young, Sero-positive.
Rheumatoid Arthritis Dr Chandini Rao Consultant Rheumatologist.
( Slow Acting Anti-inflammatory Drugs ). OBJECTIVES At the end of the lecture the students should Define DMARDs Describe the classification of this group.
Dr. M Jokar RA - Definition u Chronic systemic inflammatory disorder u Unknown etiology u Synovium affected u Joint Deformity u Extra-articular.
Dr.B.V.Venkataraman Professor in Pharmacology International Medical School Faculti Perubatan, New BEL Rd Bangalore Drugs.
BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF General Features & Conditions to use antirheumatic Low doses are commonly used early in the course of the disease.
Disease modified Anti-rheumatic drugs ( DMARD)
IMMUNOSUPPRESSANT THERAPY DR FATAI OLUYADI USMLEINCLINED.COM 1.
Rheumatoid Arthritis Christine Aranyi and Rebecca Boon State university of new york institute of technology Pathophysiolog y Rheumatoid Arthritis (RA)
Advances in the Treatment of Crohn’s Disease GASTROENTEROLOGY 2004;126:1574–1581.
Non-steroidal anti-inflammatory drugs
Treatment Goal of treatment reduce inflammation and pain, preservation of function, prevention of deformity.
Rheumatoid arthritis (RA).  Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that may affect many tissues and organs, but principally.
Disease Modifying Antirheumatic drugs. At the end of the lecture the students should: Know the pathogenesis of rheumatoid joint damage Emphasize the rational.
Adalimumab Drugbank ID : DB00051
Rheumatoid Arthritis Hayley Evans, CMCBI, King’s College London, UK
DMARDs Disease-Modifying Anti rheumatic Drugs
Gout Is recurrent inflammatory disorder characterized by
Rheumatoid Arthritis: Management and New Therapies
Pembrolizumab Drugbank ID :DB09037 Half life : 28 days.
Disease Modifying Anti-rheumatic drugs
Rheumatic Arthritis (RA)
Natalizumab (Approved, Investigational)
Vedolizumab Protein chemical formula : C6528H10072N1732O2042S42
Retinoids used in dermatology
Monoclonal Antibodies
Treatment Goal of treatment reduce inflammation and pain
Epidemiology of rheumatoid arthritis
Drug Therapy of Rheumatoid Arthritis
Antimetabolite drug Inhibits dihydrofolate reductase
Anti-fungal agents Problem: Fungi are eukaryotes
Rheumatoid ARHTRITIS Therapeutics 4th stage.
Psoriasis What’s New Dr. Vincent P Beltrani
Anti-tumor necrosis factor therapy
Anti-integrin therapy in inflammatory bowel disease
Antirheumatic drugs Dr Sura Al Zoubi
“Drugs used in IBD and biological and immune therapy of IBD ”
Disease Modifying Anti-rheumatic drugs
Presentation transcript:

Epidemiology of rheumatoid arthritis DMARDS Epidemiology of rheumatoid arthritis Affects 1-2% of the adult population Is more common among women than in men(2-3 times) Usually appears between ages 25 and 40 years The incidence also increases with age, peaking between the 4th and 6th decades Causes pain, disability and loss of function

dmards ilos Emphasize the rationale for early treatment of RA Classify drugs used for treatment of RA Compare and contrast the advantages and disadvantages of NAISDs, Steroids and DMARDS in treatment of RA Explore the pharmacokinetic aspects and pharmacodynamic effects of selected DMARDs

Rheumatoid arthritis RA is a chronic autoimmune disorder in which the normal immune response is directed against an individual's own tissue leading to:- Decline in functional status Work disability Co-morbidity Increased mortality

Rationale for early treatment Joint damage is an early phenomenon of rheumatoid arthritis Joint erosions occur in up to 93% of patients within less than 2 years of disease activity Disability occurs early – 50% of patients with RA will be work disabled at 10 years Severe disease is associated with increased mortality Early and aggressive treatment may have long-term benefits

pathogenesis Glucocorticoids Tocilizumab Hydroxychloroquine Infliximab Methotrexate

Drugs for Rheumatoid Arthritis classification Drugs for Rheumatoid Arthritis DMARDs Classical Biologic NSAIDs Glucocorticoids

nsaids Do not slow the progression of the disease Provide partial relief of pain and stiffness Rapid onset of action Used in acute cases to relieve inflammation & pain Chronic use should be minimized due to the possibility of side effects, including gastritis and peptic ulcer disease as well as impairment of renal function.

Glucocorticoids Anti-inflammatory drugs with an intermediate rate of action (slower than NSAIDs but faster than other DMARDs) Therapeutic action involves their anti- inflammatory & immunosuppressant effect May be administered in low to moderate doses to achieve rapid disease control before the onset of fully effective DMARD therapy Reserved for temporary control of severe exacerbations and long-term use in patients with severe disease not controlled by other agents Corticosteroids are too toxic for routine chronic use

DMARDs Classification of dmards Biologic Classical Methotrexate Hydroxychloroquine Infliximab Tocilizumab

General features Used when the disease is progressing & causing deformities Can not repair the existing damage, but prevent further deformity Have no analgesic effects Their effects take from 6 weeks up to 6 months to be evident

methotrexate “Gold standard” for DMARD therapy & is the first-line DMARD for treating RA and is used in 50–70% of patients Active in RA at much lower doses than those needed in cancer chemotherapy

methotrexate mechanism Inhibits dihydrofolate reductase Reduces thymidine & purine synthesis But at the dosages used for the treatment of RA, methotrexate has been shown to stimulate adenosine release from cells, producing an anti-inflammatory effect. Inhibition of polymorphonuclear chemotaxis Inhibition of T-Cells (cell-mediated immune reactions)

methotrexate pharmacokinetics Approximately 70% absorbed after oral administration Metabolized to a less active hydroxylated product Half-life is usually only 6–9 hours Excreted principally in the urine, but up to 30% may be excreted in bile. Given 7.5 – 30 mg weekly

adrs Bone marrow suppression Dyspepsia, Mucosal ulcers Hepatotoxicity Pneumonitis Teratogenicity Leukopenia, anemia, stomatitis, GI ulcerations, and alopecia are probably the result of inhibiting cellular proliferation Folic acid reduces GI & bone marrow effects Monitoring:-Full blood count, ALT, Creatinine

hydroxychloroquine mechanism Stabilization of lysosomal enzyme activity Trapping free radicals Suppression of T lymphocyte cells response to mitogens Inhibition of leukocyte chemotaxis Dampens antigen–antibody reactions at sites of inflammation

hydroxychloroquine pharmacokinetics Rapidly absorbed and 50% protein-bound Extensively tissue-bound, particularly in melanin-containing tissues such as the eyes Elimination half-life of up to 45 days Highly concentrated within cells→ increases intracellular pH

hydroxychloroquine Clinical uses Has not been shown to delay radiographic progression of disease Generally used for treatment of early, mild disease or as adjunctive therapy in combination with other DMARDs. Used in increasing methotrxate efficacy 6 month response, mild antirheumatic effect

adrs Least toxic, no blood tests is required Nausea & vomiting Corneal deposits Irreversible retinal damage, rare Ophthalmologic evaluation every 6 months

Biologic disease modifier Genetically engineered drugs that are used to modify imbalances of the immune system in autoimmune diseases. Some of these agents block, or modify the activity of selected cells in the immune system Others work by blocking cytokines, that send signals between those cells They are expensive

Biologic disease modifier classification T-cell modulating drug (abatacept) B-cell cytotoxic agent (rituximab) Anti-IL-6 receptor antibody (tocilizumab) TNF- blocking agents (infliximab)

Tnfα blocking agents Role of Tnf on joint destruction

Tnfα blocking agents infliximab mechanism A chimeric IgG1 monoclonal antibody (25% mouse, 75% human) mechanism It complexes with soluble TNF-α (and possibly membrane- bound TNF-α)and prevents its interaction with the cell surface receptors This results in down-regulation of macrophage and T-cell function.

Monoclonal Antibody directed against TNF-alpha: Infliximab (Remicade ®), Adalimumab (Humira®) Engineered Soluble TNF Receptor Etanercept (Enbrel®) Soluble TNF-Receptors serve as a balance to TNF TNF SIGNAL

infliximab pharmacokinetics Given as an intravenous infusion with “induction” at 0, 2, and 6 weeks and maintenance every 8 weeks thereafter. Terminal half-life is 9–12 days After intermittent administration elicits human antichimeric antibodies in up to 62% of patients Concurrent therapy with methotrexate decreases the prevalence of human antichimeric antibodies

infliximab Clinical uses Infliximab is approved for use in RA, Ankylosing spnodilytis, Crohn’s disease, ulcerative colitis, It could be cobmined with methotrexate, hydroxychloroquine and other non biological DMARDs

infliximab adrs Upper respiratory tract infections Activation of latent tuberculosis Infusion site reaction Headache Cough Increase the risk of skin cancers—including melanoma

tocilizumab IL-6 is a proinflammatory cytokine implicated in the pathogenesis of RA, With detrimental effects on both joint inflammation and cartilage damage Tocilizumab binds to membrane IL-6 receptors, blocking the activity of IL-6 in mediating signals that affect cytokine production, osteoclast activation Half-life is dose- dependent Given as monthly IV

tocilizumab Clinical uses Used as monotherapy in adult with rheumatoid arthritis or in children over 2 years with systemic juvenile arthritis In combination with methotrexate or other non biologic anti-rheumatic drugs in patients with active rheumatoid arthritis not responding to TNF blockers or other biologic drugs

tocilizumab adrs Serious infections ( bacterial, tuberculosis ,fungal ) Infusion reactions Increase in cholesterol level Neutropenia, and thrombocytopenia (reversible upon stopping the drug) Decrease in WBCs Increase in liver enzymes Blood tests will be used monthly for increase in cholesterol, liver enzymes & decrease in WBCs

tocilizumab Drug interactions IL-6 inhibits CYP450 Tocilizumab restores the activity of the enzyme (essential for the metabolism of some drugs such as cyclosporine, warfarin).

Treat -to -target strategy?